People who consumed the highest amounts of low- and no-calorie sweeteners experienced 62 percent faster cognitive decline over eight years compared to those who consumed the least, with the sharpest effects concentrated in adults under age 60. The finding, drawn from three waves of cognitive testing in the ELSA-Brasil cohort between 2008 and 2019, adds a specific and troubling data point to a long-simmering question about whether sugar substitutes carry hidden neurological costs. For the millions of people who rely on these products daily, the results land without clear guidance on what to do next.
Why the under-60 memory gap demands attention now
The age split is what makes this study harder to dismiss as background noise. Adults under 60 in the highest intake group showed cognitive aging roughly 1.6 years faster than their lowest-intake peers. That gap was measured across memory, verbal fluency, and executive function, not just one narrow test. Among participants over 60, no such association appeared, according to Harvard Health Publishing. The divergence raises a pointed question: is something about mid-life biology making younger brains more vulnerable to these compounds?
One plausible explanation centers on vascular risk. Adults in their 40s and 50s are at the stage when high blood pressure, insulin resistance, and early arterial stiffness begin to accumulate, often without diagnosis. If sweeteners alter cerebral blood-flow regulation or amplify inflammation during this critical window, the cognitive effects could be magnified in ways that older adults, whose decline is already driven by established neurodegenerative processes, would not show on standard tests. Testing this idea would require adding serial carotid ultrasound or cerebral perfusion imaging to future ELSA-Brasil waves, tools that the cohort has not yet deployed for this purpose.
Eight years of data from ELSA-Brasil and the Framingham trail
The study, published in Neurology, tracked intake of seven sweetener compounds through repeated food-frequency questionnaires across three assessment windows: 2008 to 2010, 2012 to 2014, and 2017 to 2019. Cognition was measured using a battery that included an adapted CERAD word-list task for memory, verbal fluency tests, and trail-making assessments, as described in the ELSA-Brasil protocol. Higher total sweetener intake was associated with faster decline across these domains, with the strongest signal in memory performance.
This is not the first time artificially sweetened products have been linked to brain outcomes. An earlier prospective analysis of the Framingham Heart Study Offspring cohort found that consumption of artificially sweetened beverages was associated with higher risks of stroke and dementia. That study, supported by the National Heart, Lung, and Blood Institute, examined beverage-level exposure rather than individual sweetener compounds, but the direction of the association was consistent. The ELSA-Brasil work sharpens the picture by tracking seven specific sweeteners and by isolating the age group where the effect appears strongest.
Separate documentation of sweetener usage patterns among non-diabetic ELSA-Brasil participants has also highlighted how food-frequency questionnaires capture these exposures, including the prevalence of different sweetener types and the correlates of heavy use. That upstream work helps establish that the exposure measurement, while imperfect, is grounded in validated cohort methods rather than a single self-report snapshot.
Gaps in the sweetener-cognition evidence
The most pressing unresolved question is reverse causation. People who consume large quantities of artificial sweeteners often do so because they already have metabolic risk factors, including prediabetes or obesity, that independently accelerate cognitive decline. The ELSA-Brasil analysis adjusted for known confounders, but individual cognitive scores and the exact intake thresholds that defined the highest consumption group have not been released in publicly accessible summaries. Without those details, outside researchers cannot fully evaluate whether residual confounding by undiagnosed diabetes or other metabolic conditions explains part of the signal.
A second gap involves biological mechanism. No gut-microbiome data, inflammatory biomarker panels, or neuroimaging results have been published alongside the cognitive waves. Animal studies have suggested that certain sweeteners alter gut bacteria in ways that could affect brain function, but the ELSA-Brasil cohort has not yet connected those dots in human participants. The validation metrics for the food-frequency questionnaire, specifically how well it captures brand-level sweetener doses, also remain unpublished in primary cohort documentation.
There are also questions about generalizability. ELSA-Brasil participants are public servants and retirees, a group that tends to be more educated and to have more stable employment than the broader Brazilian population. Their dietary patterns, access to healthcare, and baseline cognitive reserve may differ from those of people in lower-income or rural settings. Whether similar associations would emerge in cohorts with different ethnic, socioeconomic, or dietary profiles is not yet known.
Finally, the study design cannot distinguish among the many products that deliver these additives. Sweeteners in diet sodas, “light” yogurts, protein powders, and tabletop packets are all lumped into a single exposure metric. If certain formulations or delivery vehicles are more harmful than others, the current data cannot tease that apart. Nor can it address potential interactions with ultra-processed foods, sleep quality, or chronic stress, all of which may shape brain aging trajectories.
What this means for everyday sweetener use
For readers who use diet sodas, tabletop sweeteners, or sugar-free packaged foods daily, the practical takeaway is limited but real. This study does not prove that sweeteners cause memory loss. It does show a dose-dependent association between higher intake and faster decline in several cognitive domains among middle-aged adults, echoing earlier signals from beverage-focused research. In public-health terms, that is enough to justify caution, especially for people in their 40s and 50s who already carry metabolic risks.
One reasonable response is to treat low- and no-calorie sweeteners as transitional tools rather than permanent fixtures. For someone drinking multiple regular sodas a day, switching first to diet versions may still reduce short-term calorie and glucose load. But the new findings suggest that the ultimate goal should be to move toward water, unsweetened tea, or coffee, and to rely more on whole foods than on “sugar-free” processed products.
Another is to focus on total sweetness exposure, not just calories. The brain and gut respond to sweet taste even when no sugar is present, and chronic overstimulation of those pathways may carry its own risks. Gradually dialing down how sweet foods and beverages taste-by diluting juices, choosing plain yogurt over flavored, or skipping sweeteners in coffee-may help reset preferences and reduce reliance on both sugar and its substitutes.
For people with diabetes, the calculus is more complicated. Uncontrolled blood sugar is a well-established driver of cognitive decline, and replacing sugar with low-calorie sweeteners can be an important part of glucose management. In that context, the new data argue not for abandoning sweeteners outright but for using them strategically, under medical guidance, while also investing in dietary patterns that emphasize fiber, healthy fats, and minimally processed foods.
Clinicians and policymakers, meanwhile, face a familiar dilemma: how to communicate emerging risk without overstepping the evidence. Regulatory agencies have historically evaluated sweeteners primarily for cancer and acute toxicity, not for subtle, long-term effects on the brain. The ELSA-Brasil findings, combined with prior cohort work, point to the need for updated safety assessments that incorporate cognitive outcomes and that pay particular attention to mid-life exposure.
For now, the most defensible advice is pragmatic rather than alarmist. If you are under 60 and use artificial sweeteners heavily, consider this a nudge to reassess habits, especially if you also have high blood pressure, elevated blood sugar, or a family history of dementia. Cutting back will not guarantee protection, and continuing to use them will not guarantee harm. But in a world where many of us already face stacked risks to brain health-from sedentary work to chronic stress-trimming one potentially problematic exposure may be a step worth taking while researchers work to clarify the long-term cognitive costs.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
